iCAD has announced that more than 4,000 non-melanoma skin cancer (NMSC) patients have been treated using its Xoft Axxent electronic brachytherapy system, which offers an alternative, pain-free treatment option for patients who may not be candidates for surgery or who are concerned with cosmetic outcomes associated with surgery.
The system incorporates a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs.
The Xoft system is claimed to be the only electronic brachytherapy (eBx) system with peer-reviewed published data in support of this application.
The unique mobility of the system allows it to be easily transported to multiple locations and stored when not in use.
iCAD president and CEO Ken Ferry said these latest milestones demonstrate the growing clinical support for the Xoft system as an attractive, non-surgical alternative to treat non-melanoma skin cancer.
"Through strategic partnerships and a growing customer base, the Xoft System is now available to an expanded patient population at both radiation oncology and dermatology centers across the country," Ferry added.
"The increased adoption of the Xoft System by leading clinicians combined with positive clinical data supports the continued growth and more widespread adoption of electronic brachytherapy."
The system is cleared by the US Food and Drug Administration and CE marked in the EU for treating an early-stage breast cancer, gynecological cancers and non-melanoma skin cancer.